Live feed06:05:00·13dPRReleasevia QuantisnowMannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPFByQuantisnow·Wall Street's wire, on your screen.MNKD· MannKind CorporationHealth Care
